Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
IV

NASDAQ · IVA

Inventiva S.A.

Healthcare · Biotechnology

$4.68

Up+$0.03 (+0.65%)

Updated Aug 22, 2026, 8:14 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
233.4M
P/E ratio
-1.32
Dividend yield
0.00%
52-week range
$3.35 – $7.98
Volume
461.4K
Avg. volume
247.07K

Price performance

IVA price history

1M range · 21 trading sessions · Daily adjusted prices

IVA closed at $4.68 after 21 trading sessions, up 4.93% for the selected period.

Last close
$4.68
Period change
+4.93%
Period low
$4.25
Period high
$4.80
Daily close
View OHLC price history
IVA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 21, 2026$4.65$4.78$4.63$4.68461.4K
Aug 20, 2026$4.74$4.74$4.57$4.65517.34K
Aug 19, 2026$4.73$4.79$4.69$4.76575.2K
Aug 18, 2026$4.64$4.68$4.45$4.64770.56K
Aug 17, 2026$4.69$4.75$4.63$4.70554.9K
Aug 14, 2026$4.63$4.65$4.54$4.60573.82K
Aug 13, 2026$4.73$4.73$4.591$4.60514.77K
Aug 12, 2026$4.72$4.82$4.67$4.68414.8K
Aug 11, 2026$4.82$4.84$4.72$4.72382.92K
Aug 10, 2026$4.81$4.88$4.69$4.75443.67K
Aug 7, 2026$4.90$4.94$4.80$4.80579.07K
Aug 6, 2026$4.77$4.84$4.57$4.66380.66K
Aug 5, 2026$4.54$4.745$4.54$4.72707.58K
Aug 4, 2026$4.25$4.605$4.22$4.511.02M
Aug 3, 2026$4.39$4.46$4.25$4.251.01M
Jul 31, 2026$4.62$4.63$4.34$4.481.35M
Jul 30, 2026$4.51$4.66$4.48$4.62694.62K
Jul 29, 2026$4.45$4.70$4.42$4.511.18M
Jul 28, 2026$4.58$4.6599$4.52$4.64928.29K
Jul 27, 2026$4.45$4.68$4.425$4.60707.17K
Jul 24, 2026$4.44$4.545$4.38$4.46667.37K

Latest IVA news

The latest Smart Investors Daily articles mentioning IVA.

Stock researchCompany · Overview

IVA research

Overview

Company profile and research snapshot.

Company profile

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.33
Implied upside
—
Analysts
—
IVA recent ratings
DateFirmRatingTarget
Jul 9, 2026KBC SECURITIESBuy—
Jun 30, 2026TD COWENBuy—
Jun 28, 2026PORTZAMPARC BNP PARIBASBuy—
Jun 23, 2026PIPER SANDLER COMPANIESOverweight—
May 26, 2026GUGGENHEIM SECURITIES LLCBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 6, 2026

Claret Capital Partners provides €30m financing to Carvolix to accelerate commercialization of medtech portfolio

Claret Capital Partners provides €30m financing to Carvolix to accelerate commercialization of medtech portfolio Carvolix is a listed French commercial- and clinical-stage medical technology companyDeveloping breakthrough AI-driven mini-robots and biomimetic implants to revolutionize interventional cardiology and the treatment of ischaemic stroke Lead technology, TAVIpilot, an FDA-cleared, easy-to-use, AI-driven intraoperative software for TAVI (Transcatheter Aortic Valve Implantation) procedure

Yahoo · Jul 30, 2026

Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million. All other information in the pres

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By